On November 4, Boehringer Ingelheim and China Biopharmaceutical Co., Ltd. announced that they have reached a strategic multi-project option and licensing agreement to advance a potential next-generation cancer treatment plan based on antibody-conjugated drugs and T-cell connector technology.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.